胃癌发生发展中的胃部微生物群及其临床意义
本文综述胃部微生物群在胃癌发生发展中的作用。幽门螺杆菌被公认为胃癌发生的诱因,但越来越多的证据表明胃黏膜定植微生物参与疾病进展,胃部微生物群失调可能贯穿从癌前病变到胃恶性肿瘤的全过程。文章评估了胃部微生物用于胃癌诊断、预后和治疗转化的潜力,并指出当前概念模糊和局限,强调调节微生物是胃癌防治的新兴前沿,需未来深入研究。
要点
- 幽门螺杆菌是胃癌发生的公认诱因,但胃黏膜定植微生物也参与疾病进展。
- 胃部微生物群失调可能贯穿从癌前病变到胃恶性肿瘤的全过程。
- 调节微生物是胃癌预防和管理的新兴前沿,需未来深入研究。
核心结论
- 胃部微生物群失调可能贯穿从癌前病变到胃恶性肿瘤的全过程。
- 调节微生物是胃癌预防和管理的新兴且有前景的前沿,需未来深入研究。
研究设计与样本
- 综述总结当前关于胃部微生物群在胃癌发生发展中作用的认识。
主要发现
- 幽门螺杆菌被广泛认为是胃癌发生的诱因。
- 越来越多的证据表明胃黏膜定植微生物参与疾病进展。
- 胃部微生物群失调可能贯穿从癌前病变到胃恶性肿瘤的全过程。
临床怎么用
- 评估使用胃部微生物进行胃癌诊断、预后和治疗的潜在转化和临床意义。
局限性
- 文中讨论了当前的概念模糊和局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastric cancer (GC) is one of the most common malignancies and a prominent cause of cancer mortality worldwide. A distinctive characteristic of GC is its intimate association with commensal microbial community. Although Helicobacter pylori is widely recognised as an inciting factor of the onset of gastric carcinogenesis, increasing evidence has indicated the substantial involvement of microbes that reside in the gastric mucosa during disease progression. In particular, dysregulation in gastric microbiota could play pivotal roles throughout the whole carcinogenic processes, from the development of precancerous lesions to gastric malignancy. Here, current understanding of the gastric microbiota in GC development is summarised. Potential translational and clinical implications of using gastric microbes for GC diagnosis, prognosis and therapeutics are also evaluated, with further discussion on conceptual haziness and limitations at present. Finally, we highlight that modulating microbes is a novel and promising frontier for the prevention and management of GC, which necessitates future in-depth investigations.
引用
- Zeng R, Gou H, Lau HCH, et al. Stomach microbiota in gastric cancer development and clinical implications. Gut. 2024. PMID: 38886045. doi:10.1136/gutjnl-2024-332815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。